OTC Naloxone and Community Access

The PQS Quality Corner Show welcomes Thomas Franko, PharmD, Associate Professor of Pharmacy Practice at Wilkes University on the podcast to talk about the upcoming release of OTC Naloxone and what that means for pharmacists in improving community access. 

Podcast Host Nick Dorich, PharmD, PQS Associate Director of Pharmacy Accounts also asks Franko about where Naloxone will fit in the pharmacy setting and how pharmacists can tackle education on this medicine. 

Transcript

Copy Transcript Copied

00:00:00:14 - 00:00:20:13
Speaker 1
There's no reason that pharmacists shouldn't be able to prescribe and manage buprenorphine, and there's no reason pharmacists shouldn't be able to get naloxone out there. This is the number one public health crisis in the country, and we are the most accessible health care provider. We had recent data show that 90% of the population lives within five miles of a pharmacy.

00:00:20:23 - 00:00:36:11
Speaker 1
So this is an amazing, amazing opportunity for pharmacists to get involved, really show what we can do. This is a practice advancing opportunity for us, and it's a way to not only advance our practice but to save lives. So this is a win win and we should really take advantage of it.

00:00:39:07 - 00:01:04:01
Speaker 2
Welcome to the Pharmacy Quality Solutions Quality corner show where quality measurement leads to better patient outcomes. This show will be your go to source for all things related to quality improvement and medication use and health care. We will hit on trending topics as they relate to performance measurements and find common ground for payers and practitioners. We will discuss how the equipped platform can help you with your performance goals.

00:01:04:10 - 00:01:25:14
Speaker 2
We will also make sure to keep you up to date on pharmacy quality news. Please note that the topics discussed are based on the information available at the date and time of reporting. Information or guidelines are updated periodically and we will always recommend that our listeners research and review any guidelines that are newly published. Buckle up and put your thinking cap on.

00:01:25:23 - 00:01:28:00
Speaker 2
The Quality Corner show starts now.

00:01:38:07 - 00:02:16:07
Speaker 3
Hello Quality Corner Show listeners Welcome to the PQS podcast, where we focus on medication use, quality improvement and how we can utilize pharmacists to improve patient health outcomes. I'm your host, Nick Dortch. Now, through numerous episodes of The Quality Corner Show, we have covered pain management and substance Use Disorder, a growing and concerning public health crisis. On March 29, the FDA announced they had approved the first OTC, Narcan or Naloxone product, and I immediately wanted to make sure that we could cover this topic on the show, as it's been pretty related to many of our prior conversation sessions.

00:02:16:19 - 00:02:48:00
Speaker 3
This has potentially massive implications for patients and may become a frequent point of discussion for our practicing community. Pharmacist. However, while this should be a positive update for patients, families and caregivers, it is not without its own challenges or remaining questions that we're going to have to figure out. So to help us address some of those questions and address the impact for our community, I've brought along our guests for today's show, and that is Dr. Tom Franco, associate professor of pharmacy practice at Wilkes University.

00:02:48:06 - 00:02:49:20
Speaker 3
Tom, welcome to the show.

00:02:50:21 - 00:02:53:12
Speaker 1
Thanks for having me, Nick. I'm really excited to be here today.

00:02:54:12 - 00:03:22:05
Speaker 3
Excellent. You and I had a chance to meet at the most recent APhA meeting. We met through some mutual friends and turns out we've got a lot of mutual friends, but also a lot of interest around the public health space. So and you, you do a podcast of yourself that yourself that we may talk about later. So this was an item where when I saw this notice about OTC Narcan, it was like, Well, hey, I got to talk to Tom, I got to introduce him to our community at the Quality Corner show.

00:03:22:09 - 00:03:29:07
Speaker 3
But let's hear a little bit about you. So, Tom, what's your background as a pharmacist and what is it what is it that you do in your current role?

00:03:30:01 - 00:03:57:09
Speaker 1
So I graduated from the Philadelphia College of Pharmacy. What seems like a long time ago now, back in 2011, I then did one year of residency at the VA Hospital here in Wilkes-Barre. Then I went to work for Geisinger Health System for almost two years doing outpatient chronic pain management. Came over to Wilkes in 2013 and had been teaching there in the pain management substance use harm reduction area, have an elective course on it all.

00:03:57:09 - 00:04:25:18
Speaker 1
My research is in that area, especially around naloxone access, the locks on education, education of first responders on this, on this topic. And then outside of that, in more of our service capacity. I was about two years ago the coordinator of the pain palliative care and addiction CIG through AP. I'm currently the region two counselor for Roky Our Honor Society, and I'm the immediate past president of the Pennsylvania Pharmacists Association.

00:04:26:04 - 00:04:46:22
Speaker 1
So lots going on. But I love working with this topic and I think the thing that I found the most interesting is that whether it's in pain or substance use disorder, you really do see the patients get better. And to know that you had any impact on seeing that person, whether it's a pain patient put down their pain or whether it's a patient with substance use disorder, get back with their family.

00:04:47:04 - 00:04:53:24
Speaker 1
It's the most fulfilling feeling you can have. And I just love talking about this stuff and I'm really happy to talk about it today.

00:04:54:21 - 00:05:17:19
Speaker 3
That's excellent. And I'll note one of the things with pain management and substance use disorder, all those items as we talk about, it's something that could be impacting all patients, right? It does not care about race, about socioeconomic status or any of those things that that that exists. So this is something really, regardless of the practice setting that any pharmacist, whether it's community hospital and care, is something that we're going to see in across all patients.

00:05:17:19 - 00:05:36:24
Speaker 3
So it's really important for our communities, for the communities that we serve and to your point, Tom, it is an area as well where we can really help these patients get back, whether it be functionality or get back to some of that normal life that they have or help them through their recovery in their management. So this is one of those areas where I think most of us went into pharmacy to help people.

00:05:37:05 - 00:05:54:03
Speaker 3
And this is absolutely an area where we can really get the feel good feeling that really a lot of us are seeking. So, Tom, we're going to get into our conversation about OTC, Narcan or Naloxone. But first we're going to hear a quick message from the PQS team and get ready for the breakdown.

00:05:55:20 - 00:06:19:20
Speaker 2
Now it's time for the breakdown as quality corner show host little as three main topic questions. Our guests will have a chance to respond and there will be some discussion to summarize the key points this process will repeat for the second and third questions, which will wrap up the primary content for this. Then after that expect to end on a closing summary, usually containing a bonus question.

00:06:20:10 - 00:06:23:09
Speaker 2
Now that we have the start of the process, let's jump into the questions.

00:06:26:23 - 00:06:48:20
Speaker 3
All right, Tom, as stated in the introduction for this episode, we now have an OTC Naloxone product, that being the four milligram naloxone nasal spray. Now, before we get into a bunch of questions about how this impacts patients, let's first cover at a high level what is naloxone, what is this intended use and how is this going to impact the community?

00:06:49:14 - 00:07:20:22
Speaker 1
Naloxone is the reversal agent for opioid induced respiratory depression, which is the new preferred way of saying overdose. We don't want to say overdose. That can perpetuate a negative stigma, that can perpetuate shame. So to get away from that, the recommendation by various organizations, including APhA, is opioid induced respiratory depression. So that's where this medication comes in. And the real utility of it is it's a life saving medication.

00:07:20:22 - 00:07:42:24
Speaker 1
It's a life saving tool. It's just like what you would think with EpiPen. I have four nieces. They're all under ten. Two of them are highly, wildly allergic to peanuts. And EpiPen is there to not allow them to eat peanuts. And EpiPen is there in case accidentally they get exposed to it. We can get them help. We can get in treatment.

00:07:43:12 - 00:08:10:08
Speaker 1
Naloxone is the same thing the majority of the time. We're looking at folks who accidentally get exposed to this stuff. It could be a grandma who takes too much medication because she's confused. Or it could be a child who thinks that the medication is candy. This is here to help those folks, as well as folks who have a substance use disorder, get another chance at life and either get help or get treatment or get whatever they need in order to continue to have a healthy life.

00:08:11:06 - 00:08:38:14
Speaker 3
Excellent. So follow up question to this, Tom. When talking about naloxone, there are some discussions about when or who should have naloxone on hand. And like many aspects related to opioid use, there are stigmas and there are prejudices that exist. I know this is a topic that I've looked at and I've had some conversations with with our mutual friend Jeff Bradford, going back almost 15 years now and a lot at in a past time.

00:08:38:14 - 00:09:02:07
Speaker 3
There were a lot of concerns about, hey, having naloxone on hand, that's just going to lead to more overdoses. That was the concern or prejudice, which we know is really not the case here. But, Tom, the question I have for you, who should have naloxone? Is this something where every time a an opioid prescription is being dispensed from the pharmacy, should there be, you know, naloxone with it or should there be at least that conversation about access to Naloxone?

00:09:02:22 - 00:09:29:03
Speaker 1
So the answer to that is yes in multiple ways. The FDA has, I want to say maybe about two years ago now, put into the labeling for all opioid products that naloxone needs to be discussed not only at the point of dispensing, but also at the point of prescribing. So this is something that we need to that like the double tap that we need to make sure that people get with this thing too, to take a line from Zombieland.

00:09:29:03 - 00:09:57:17
Speaker 1
We have to do that. So I think that there's a lot of opportunity to get this out there. Additionally, back in 2017, the U.S. surgeon general came out and said that everybody should have naloxone. You just never know when you're going to be walking around and you unfortunately might see something. What I try to get across to students is anytime you have somebody who is getting an opioid, the two things that we should always give them are naloxone and a laxative.

00:09:58:01 - 00:10:19:16
Speaker 1
Just because the recipe for depression and constipation are two side effects associated with opioids. So a long winded way of saying yes, people who are on opioids should have this. I hope they never have to use it and it just gets tossed after it expires. But it's one of those things that we're really happy if you do need it, that you have it.

00:10:20:16 - 00:10:51:06
Speaker 3
Excellent. So let's talk about having the naloxone, right? So if every patient getting an opioid should have naloxone, in theory, OTC naloxone should be a lifesaver and it should be a game changer, right? Well, maybe not. And even with this announcement from the FDA, there's been questions or concerns from pharmacists, from other health providers, from public health officials as to, well, it being available OTC, that's not the same thing as patients having access to it.

00:10:51:12 - 00:11:14:06
Speaker 3
Right. So when it comes to OTC naloxone, what questions or concerns do exist? Is this something where patients are really going to be able to access it? Is it affordable? Is it do they have the education that they can get from their provider, maybe a pharmacist? And is that supported? Is that compensated so that patients can really use the product accordingly?

00:11:14:24 - 00:11:36:24
Speaker 1
Those are three really big questions that we still don't really know the answer to the product as of recording. This is currently not yet on the shelf. We know it's coming, but a lot of those things we don't know. A recent, I think it was on NBC story that I saw said that the price point was going to be under $50.

00:11:37:08 - 00:12:01:18
Speaker 1
Now whether that means $49.99, that's to be debated. But still $50 is really expensive for a lot of people, especially during the current times that we live in. So money is going to certainly be part of it. One thing that I've been trying to tell a lot of patients, a lot of my patients are financially strapped. They're really pressed for cash is if you can't afford the over-the-counter stuff when it comes out.

00:12:02:00 - 00:12:28:12
Speaker 1
There are still a variety of prescription products available that you could apply your insurance to, especially if you are a medicaid patient. In Pennsylvania, Medicaid patients have zero co-pay when they get the prescription versions. So that's something we can certainly help with with cost education in hearing the word about town is that the education may get printed on the box that gets put on the shelf, so the box might get bigger because of that.

00:12:28:24 - 00:12:47:23
Speaker 1
Now, having that education there is great. I think that you can never supplement the education from a pharmacist. We are we are undoubtedly the teachers of the health care community, so I'd still encourage people to talk to their local community pharmacist about naloxone and how to use it, and more importantly, what to expect when you do give this to somebody.

00:12:48:17 - 00:13:04:05
Speaker 1
But the bigger question that I have is if the box is bigger, that's going to take up more room on the shelf. So where are pharmacists or any place a gas station convenience store, where are they going to put it? And that's the big question is where where are the things going to be putting it? I had a nice conversation.

00:13:04:12 - 00:13:20:18
Speaker 1
I'm not sure if you if you know, or maybe we talked about it. APhA with Mark Garofoli out of West Virginia. I we were talking about where where do pharmacies, where are pharmacies going to stock this? And it's is going to be on the shelf. Is it going to be behind the plexiglass, like the razor blades? Is it going to be behind the counter?

00:13:21:02 - 00:13:37:11
Speaker 1
We don't know. So I think it's something that what I would advocate to to your listeners and especially in community practice, do everything you can to make this stuff visible, get it out there and do everything you can to make sure patients know it's there. They can come and get it and they can talk to you about it.

00:13:38:04 - 00:14:00:18
Speaker 3
Yeah, it's all the great points, Tom, And it's been my questions or concerns from this, right? Hey, it's OTC, but if that price point is higher than what patients could previously get it through insurance, well, it's more accessible physically, but not more accessible financially. Right. That can be a barrier there. I have some my own thoughts or questions about, hey, where does it physically go in the pharmacy?

00:14:00:24 - 00:14:24:03
Speaker 3
Because, you know, to your point, if it's behind the counter at the pharmacy or even there may be medications for, say, tobacco cessation. Right. They may be behind the counter at the front of the pharmacy or you're having a cashier that isn't a trained health care professional. Right. And it's that that part there where, yes, they may have better access to the medication, but if they don't know how to use it or if they're not getting the correct product, it's not very useful.

00:14:24:11 - 00:14:43:08
Speaker 3
So we've got a lot of different considerations there. I guess, Tom, if there's like one big question or one burning item that you'd really like to make sure happens to ensure, is is there one item that you want to make sure and I'm putting you on the spot here with that for just for just one, but is there one thing you can think of that needs to be addressed or to to ensure access immediate?

00:14:44:10 - 00:15:12:04
Speaker 1
You really are putting me on the spot with that one. Nick Honestly, I think that you could look at cost, you could look at education, you can look at all of that. This is going to come down to stigma. It's really going to come down to that because if if there's still a stigma that having this labels you as some as, you know, a less than or somebody with an addiction, which unfortunately that stigma out there exists, we're getting better at fixing it, but it still exists.

00:15:12:20 - 00:15:34:14
Speaker 1
That's something that's going to prohibit access. You could put this thing on a on a table in the middle of town square and people still won't come and get it if that's the case. So we really need to continue to reduce stigma from a public and professional setting so that when you do go in and you do purchase this, it's no different than if you walked into a pharmacy and picked up a bottle of aspirin.

00:15:34:21 - 00:15:37:04
Speaker 1
It has to have the same connotation behind it.

00:15:38:08 - 00:16:02:23
Speaker 3
Excellent. Well, Tom, I'll move us to our third. And I guess final question related to this topic. Our show, the Quality Corner Show, we always focused on what I perceived to be the most important one in health care, and that is improving patient health outcomes. Now, with typically when we're talking about outcomes on this show, it's usually related to medication adherence or clinical guidelines.

00:16:03:13 - 00:16:21:18
Speaker 3
In this case, a medication moving to an OTC designation is a little bit different. But how can we, as I guess, practitioners, how can we measure this either subjectively or objectively, how a move for naloxone to being an OTC product? How does this improve patient outcomes?

00:16:22:15 - 00:16:48:01
Speaker 1
My opinion, the best way that we can track at least initially, whether this move was whatever you wanna call it, worth it, did something, whatever is, it's got to start objectively about getting this product into the hands of patients. That's that's got to be the first thing. If the whole move of this was to improve access, then we should be tracking well, how much of it is actually out there in the community.

00:16:48:15 - 00:17:10:20
Speaker 1
And I think that the the potential barrier that you're going to see with that is the same barrier that we saw when the a lot of the the data 2000 stuff started to go away for buprenorphine physicians who are already prescribing buprenorphine, we're going to prescribe it. It was we didn't see any new prescribing or jumps in prescribing since that.

00:17:11:14 - 00:17:33:09
Speaker 1
I'm hoping we don't see the same thing here. But when I look at what happened with buprenorphine and I look at what's happening here and I see, well, there are medication that are reducing barriers to ensure that patients get them and they're not going out there. This is a great opportunity for pharmacists and this is why we should advocate for this stuff, for pharmacists to fill the gap.

00:17:33:20 - 00:17:53:19
Speaker 1
There's no reason that pharmacists shouldn't be able to prescribe and manage buprenorphine, and there's no reason pharmacists shouldn't be able to get naloxone out there. This is the number one public health crisis in the country, and we are the most accessible health care provider We had recent data show that 90% of the population lives within five miles of a pharmacy.

00:17:54:05 - 00:18:09:18
Speaker 1
So this is an amazing, amazing opportunity for pharmacists to get involved, really show what we can do. This is a practice advancing opportunity for us, and it's a way to not only advance our practice but to save lives. So this is a win win and we should really take advantage of it.

00:18:10:07 - 00:18:39:06
Speaker 3
That's excellent. Now, Tom, while you're here and while you're on while you're on a soapbox here, let's call it what's I mean, pharmacist being able to prescribe what else do we need to have occur to really fundamentally change patient management for opioid use disorder or for other substance use disorder? Naloxone? I'm going OTC is a great step, but is there something else you can point to to say to the larger community and perhaps to our legislators, be it either locally, on a state level or on a more federal level?

00:18:39:19 - 00:18:47:12
Speaker 3
What else is on your wish list? Is there another item that you can point to aside from, as you just shared, pharmacist prescribing for some of these medications?

00:18:49:02 - 00:19:14:05
Speaker 1
Oh, I'd say that. Well, there's a lot that I could say. You know, you and I are friends with Jeff, so you know that that that where that can go. I think looking at if you want to call it pie in the sky type things there, there's a lot of data mounting for safe injection sites. That's where we're seeing a lot of data or I think a better phrase would be comprehensive user engagement site.

00:19:15:11 - 00:19:38:07
Speaker 1
This way we know that. We know people are going to use drugs. We know that that's the thing. Just say no. In the war on drugs totally didn't work. So we would rather somebody use in a place where there's a health care provider where we know they're not going to die, where we know they're not going to contract any, you know, anything like HIV or hep C, and they have opportunities then to get facilitated right into treatment right from there.

00:19:38:16 - 00:20:00:22
Speaker 1
And they have a lot of these sites in Canada, Australia, the EU, and there are no deaths reported from these sites. But in the U.S., it's not something that can happen. I think New York City might be opening one, but Pennsylvania, our Senate just passed a bill that would outlaw them completely. So this is something that we should look to the rest of the world to say, hey, this is not just a US problem.

00:20:00:22 - 00:20:16:06
Speaker 1
This is a worldwide issue. It's a health care condition. If we see something in another country that's working, let's let's at least trial it here to see if we can save somebody's life. So I'd say that's probably that'd be the pie in the sky idea where we can go next.

00:20:17:02 - 00:20:38:01
Speaker 3
Education is a powerful tool, and certainly it's an item where when we speak in Tom, you and I both speak with a lot of pharmacists for many different reasons, but it's an item where a lot of pharmacists and a lot of health care providers in general are wanting to focus on doing the job, taking care of the patient and doing all those all those things that are great hands on patient care.

00:20:38:10 - 00:20:59:01
Speaker 3
The reality that we know is that there's a lot of things that impact our practice as pharmacists, where decisions are made by legislators or other bodies or other organizations where they're not a health care provider, yet they're making decisions on how we practice, what we do and how we interact with patients, not just applying to substance use, but many, many other topics.

00:20:59:01 - 00:21:30:00
Speaker 3
So if you're a pharmacist, you should be getting involved with legislation, regulatory items. It's really an important aspect because if you're not doing it, someone else is going to be making those choices that impacts you and your patients. That's my soapbox on it. So. All right. Well, appreciate you jumping on the show here today. I know this is an area where you're really passionate about about this topic as you led off with the show, talking about this being an area of your your passion, your research, your work with students and in your community.

00:21:30:00 - 00:21:50:07
Speaker 3
So this you were a fantastic guest to have on to cover this topic. Again, you and I run in many of the same circles, so I'm kind of surprised it took us this long to actually meet, but I am pleased that we did finally get to meet here. Now, we cover a lot of information about Naloxone going to OTC and what's the significance of that?

00:21:50:17 - 00:22:11:22
Speaker 3
It's opioid reversal. Agent Right. So this is literally a product that can save lives. We talked about the importance of access to it, and really this should be something that should be considered same as an EpiPen, right? Where when that emergency comes around, either through an incidental or accidental or intentional use, where this can be a life saving product, that becomes really important.

00:22:12:04 - 00:22:34:16
Speaker 3
And then ultimately, this is a step it is a good step to helping patients address these instances that may come up. But we as pharmacists still need to address stigma and prejudice that may exist around opioid use or any other substance use, and also for the use of products like naloxone. So we've got more work to go. And Tom, with with that thought, I think there may be an episode in the future.

00:22:35:05 - 00:22:55:23
Speaker 3
You may maybe our friend Jeff Bradford, who's been on this show previously, we may be coming back to some kind of roundtable in the future on Hey, what else needs to change or what else we can do so that we can work in our communities to better address these items. But with that time, we get to a different part of our show that doesn't necessarily focus on our topic or health care necessarily.

00:22:56:04 - 00:22:59:11
Speaker 3
We've got some rapid fire questions. So are you ready for this?

00:23:00:07 - 00:23:00:22
Speaker 1
Let's do it.

00:23:01:15 - 00:23:05:17
Speaker 3
All right. First question. Are you a morning person or a night owl?

00:23:06:04 - 00:23:08:02
Speaker 1
Night owl, No doubt on that one.

00:23:09:12 - 00:23:11:22
Speaker 3
What's the usual bedtime? What is what does that mean for you?

00:23:12:19 - 00:23:29:21
Speaker 1
Usual bedtime. Well, there's usual bedtime that I should go to sleep. And there's usual bedtime that end up waking up on my chair, my couch, because I fell asleep watching a movie. As I got older, it's getting more and more normal. So I'd say probably bedtime now is around midnight. Probably.

00:23:30:18 - 00:23:57:20
Speaker 3
Yeah, that's me. Especially during October when it's baseball playoff season. The number of times I fall asleep on the couch watching a game, it's much higher than I would like to admit, but it happens. Tom, our second question here and I amended this question slightly based on some of your interest in things in areas where I know you have a passion for, do you prefer to read the comics or watch the Marvel Cinematic Universe movie?

00:23:58:15 - 00:24:25:24
Speaker 1
Oh, it depends on the story. I think that some some of the comics were just spectacular, but also those MCU movies have been have been some of the best films that I've seen in a long time. So I say anything game and back the films were were certainly better post Endgame. Those were those were a bit dicey. The post game ones.

00:24:26:18 - 00:24:50:19
Speaker 3
Yeah. For those not aware, Tom and I are both huge comic fans, Marvel Disney related sort of items, which is another reason why we were so quickly able to to hit it off. So we've had a lot of conversations off the books from that and I look forward to many more. And as we were setting up for this recording, we were both very, very excited to be seeing Guardians of the Galaxy three, Volume three I to make sure I get the title right.

00:24:51:10 - 00:25:04:00
Speaker 3
So yeah, I had to change. Usually it's Do you prefer the book or the movie for this question? Add to edit it slightly to better fit our our guest now Tom next question. What is your recommendation for living a healthy life?

00:25:04:20 - 00:25:31:08
Speaker 1
Take care of yourself mentally. One of one of the mentors that I have and it's somebody I truly do respect said Even if it's during the work day, Take take time for yourself. Take time to find something you can do. So something that I've done and I admit I can do better at it, is every week, once a week in my calendar I put in This is my mental health time and it can be to catch up on some reading.

00:25:31:08 - 00:25:46:04
Speaker 1
I do like reading a lot of books on leadership, but I'm also a big golfer, so that could be just getting out and hitting the range, getting out, playing nine holes just to kind of clear my head. And I think that doing that has really helped and I encourage others to do it as well.

00:25:46:20 - 00:26:08:03
Speaker 3
It's an excellent call out and obviously for our audience, many of of that many of our audience members for this show are practicing community pharmacists. And that can be something that can be difficult to build into your schedule in the work day, or it may not really be feasible, but it goes actually to my biggest recommendation for student pharmacist or recent pharmacy graduates.

00:26:08:22 - 00:26:31:14
Speaker 3
Have a hobby. Make sure you have a hobby, something when you're off of work, something that can go and be stimulating and engaging for your brain. Have it be a hobby that's not related to really anything in health care and meet some people that are outside of health care as well. That really goes a long way to having a good balance and having some kind of for lack of a better term, inner peace when you're done with the work day and resetting yourself.

00:26:32:09 - 00:26:36:15
Speaker 3
Now, Tom, final question. What is one goal that you are currently working towards?

00:26:37:07 - 00:27:01:10
Speaker 1
Oh, I'm a multitasker, so there's always something going on. But as you were saying, you know, I my I started a podcast about a year ago. It's all on Disney and Marvel and Lucasfilm and all of that great stuff. And we've been at it for about a year. So we're we're just we're starting to see some small growth.

00:27:02:02 - 00:27:20:12
Speaker 1
So we're we're I guess you could say that the goal is to just continue to grow that my wife and I are we are the stereotypical Disney adult. So we we go all the time and we just have a podcast where we talk about some objective things and some subjective things about the parks as well as the films.

00:27:21:15 - 00:27:43:16
Speaker 3
Excellent. I will be checking out. We're going to talk offline about that further. Tom I certainly am very familiar and passionate about all of those things as well as particularly the Marvel, also the Star Wars. So we'll have a lot more to cover, but wish you the best in that. And with that, Tom, I thank you for appearing on this episode of The Quality CORNISH Show for the first time, probably not the last time.

00:27:44:07 - 00:28:00:13
Speaker 3
Before we close, we need to get a couple of last bits of information from you. So if someone wants to reach out to you, whether it's about OTC Naloxone or about some of the community service projects that you're mentioning at the beginning, or maybe if they want to find your Disney podcast, it's the best way for people to contact you.

00:28:01:08 - 00:28:13:14
Speaker 1
You can reach me with emails. The best option, it's Thomas Dot Franco, AFTRA and Kayo at Wilkes WTOL Kids Dot Edu.

00:28:14:20 - 00:28:19:23
Speaker 3
Excellent. And Tom, follow up question Where can folks find your Disney podcast?

00:28:20:19 - 00:28:39:13
Speaker 1
The podcast is called Adult Meets Disney, so it's a play on Boy Meets World going back to I love that. I love right. We are available anywhere podcasts can be found. So Apple, Spotify, Amazon, Google, Stitcher, all of them. Just type in adult meets adult meets Disney and you'll find us.

00:28:40:16 - 00:29:03:06
Speaker 3
Excellent. Well, Tom, appreciate having you on the show today. Thank you for all the information. And we'll look forward to again having you on the show in the future. Certainly be interested in following your work in the space around around pain management, substance use disorder and everything related to that. So as you said, this is about saving lives and that's what pharmacies do each and every single day.

00:29:03:06 - 00:29:18:13
Speaker 3
This is just one specific way in which pharmacies do it. But for our audience, we've now wrapped up our episode for today, and we thank you for joining. We hope you listen to our next episode of The Quality Corner Show. And before we go, we have one final message from the trustee.

00:29:19:11 - 00:29:40:07
Speaker 2
The Pharmacy Quality Solutions Quality Corner show has a request for you. Our goal is to spread the word about how quality measurement can help improve health outcomes. And we need your help in sharing this podcast to friends and colleagues in the health care industry. We also want you to provide feedback, ask those questions and suggest health topics you'd like to see covered.

00:29:41:01 - 00:30:03:06
Speaker 2
If you are a health expert and you want to contribute to the show or even talk on the show, please contact us. You can email info at pharmacy quality dot com. Let us know what is on your mind, what we can address so that you are fully informed. We want you to be able to provide the best care for your patients and members, and we wish all of you listeners out there well.